glp 1 drugs for alcohol use disorder A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used weight loss, such as semaglutide, may also help reduce heavy drinking in individuals New GLP-1 Drug Studied as

Despite the benefits of GLP-1 receptor agonists, affordability and insurance coverage limitations remain critical barriers in some regions, which could potentially hinder widespread adoption

Open lines of communication are essential while setting goals and expectations regarding symptom management, medications and device outcomes

Our study using 2020 to 2025 Medicare data showed dramatic increases in out-of-pocket costs for GLP-1s, because of insurers reactions to the 2022 Inflation Reduction Act

Research on NAD+ supplementation, usually through precursors like NMN or NR, suggests potential benefits for anti-aging and cellular health

It has also been suggested that hepatic hypoinsulinemia may reduce insulin-like growth factor 1 (IGF-1) levels, which may contribute to IR as well by increasing growth hormone and IGF binding globulins (29)